Lupin gets OK in India to conduct phase 2 psoriasis trial

By Elaine Rigoli

Tampa, Fla., July 26 - Lupin Ltd. has received approval from India's Drugs Controller General to conduct phase 2 clinical trials for its psoriasis compound, LL-42 18 (Desoside-P).

The Drugs Controller General found clinical phase 1 data of LL-4218 satisfactory and has granted Lupin permission to continue phase 2 clinical trials on the molecule.

Lupin said it intends to begin clinical trials at up to six centers immediately.

LL-4218 is a pure molecule and is obtained from a plant source. It is orally bioavailable and is intended for the treatment of chronic stable plaque-type psoriasis.

The company said the total market for psoriasis is estimated to be more than $2 billion.

Mumbai, India-based Lupin is a drug manufacturing company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.